From: Evidence-based medicine and clinical fluorodeoxyglucose PET/MRI in oncology
Study | Population & setting | Reference standard | Outcome [95Â % CI] | |||
---|---|---|---|---|---|---|
PET-CT | WB-MRI | |||||
Sensitivity | PPV | Sensitivity | PPV | |||
Pfannenberg et al. (2007) [15] | Recurrent melanoma | Histology or 8 months follow-up | 85 [77–91] % | 94 % [87–97] % | 66 [56–74] % | 84 % [74–90] % |
Self-controlled study (n = 64) | ||||||
Schmidt et al. (2009) [16] | Recurrent Colorectal Cancer | Follow-up (mean 11 months) | 93 [78–98] % | 100 [86–100] % | 62 [44–77] % | 82 [61–93] % |
Self-controlled study (n = 24) | ||||||
Ng et al. (2010) [18] | Recurrent Head & Neck Cancer | Histology or 12 months follow-up | 80 [61–91] % | 77 [58–89] % | 88 [70–96] % | 81 [63–92] % |
Self-controlled study (n = 179) | ||||||
Laurent et al. (2010) [19] | Recurrent melanoma | Histology or 6 months follow-up | 83 [65–92] % | 100 [86–100] % | 90 [74–96] % | 96 [82–99] % |
Self-controlled study (n = 35) | ||||||
Jouvet et al. (2014) [20] | Recurrent melanoma | Histology or ≥6 months follow-up | 96 [79–99] % | 96 [79–99] % | 87 [68–95] % | 100 [84–100] % |
Self-controlled study (n = 37) | ||||||
Weighted averages | (n = 339) |  | 87 [81–91] % | 93 [89–96] % | 74 [67–79] % | 87 [81–91] % |